- Home
- OVID vs ABOS Comparison
OVID vs ABOS Comparison
Compare OVID & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- ABOS
- Stock Information
- Founded
- OVID 2014
- ABOS 1996
- Country
- OVID United States
- ABOS United States
- Employees
- OVID N/A
- ABOS N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- ABOS Health Care
- Exchange
- OVID Nasdaq
- ABOS Nasdaq
- Market Cap
- OVID 117.3M
- ABOS 109.6M
- IPO Year
- OVID 2017
- ABOS 2021
- Fundamental
- Price
- OVID $1.34
- ABOS $1.71
- Analyst Decision
- OVID Strong Buy
- ABOS Strong Buy
- Analyst Count
- OVID 4
- ABOS 3
- Target Price
- OVID $3.13
- ABOS $8.00
- AVG Volume (30 Days)
- OVID 1.5M
- ABOS 275.1K
- Earning Date
- OVID 11-12-2025
- ABOS 11-12-2025
- Dividend Yield
- OVID N/A
- ABOS N/A
- EPS Growth
- OVID N/A
- ABOS N/A
- EPS
- OVID N/A
- ABOS N/A
- Revenue
- OVID $6,610,000.00
- ABOS N/A
- Revenue This Year
- OVID $1,081.80
- ABOS N/A
- Revenue Next Year
- OVID N/A
- ABOS N/A
- P/E Ratio
- OVID N/A
- ABOS N/A
- Revenue Growth
- OVID 945.89
- ABOS N/A
- 52 Week Low
- OVID $0.24
- ABOS $0.86
- 52 Week High
- OVID $2.01
- ABOS $2.66
- Technical
- Relative Strength Index (RSI)
- OVID 46.30
- ABOS 39.24
- Support Level
- OVID $1.24
- ABOS $1.74
- Resistance Level
- OVID $1.39
- ABOS $2.04
- Average True Range (ATR)
- OVID 0.10
- ABOS 0.14
- MACD
- OVID -0.02
- ABOS -0.06
- Stochastic Oscillator
- OVID 45.94
- ABOS 1.49
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.